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Background: Although the usual primary clinical manifestation of Coronavirus disease
(COVID-19) is respiratory, several non-respiratory symptoms have been described,
including neuropsychiatric ones. The aim of this study was to investigate the mid-
term mental health outcomes in patients recovered from COVID-19, 3–4 months after
discharge from the University Hospital Maggiore della Carità, Novara, Italy. Furthermore,
we investigated the possible association of the mid-term mental health consequences
of the COVID-19 infection with patients’ clinical current status, persistent physical
impairment and severity of acute phase of the disease.
Methods: Prospective study involving 238 individuals recovered from COVID-19. In
the context of a multi-disciplinary approach, patients’ assessment included both a
clinical interview performed by an experienced psychiatrist, trained in the use of the
Mini-International Neuropsychiatric Interview to assess the presence of anxiety and
depressive symptoms and self-administered questionnaires: Beck Anxiety Inventory
(BAI), Beck Depression Inventory-II (BDI-II), Resilience Scale for Adults (RSA), Impact
of Event Scale (IES).
Results: At the psychiatric assessment 32.9 and 29.5% of participants showed
anxiety and depressive symptoms, respectively. Changes in appetite and sleep
patterns emerged for 15.6 and 31.2% of patients. According to the self-administered
questionnaires, 7.1% of participants had moderate-severe anxiety levels (BAI), while
10.5% hadmild to severe depression (BDI-II). Twenty-six (11%) participants were referred
to further psychiatric consultation. Psychiatric symptoms showed no correlation with
acute COVID-19 severity; in our sample patients with depressive symptoms at the clinical
interview, as well as those with mild to severe levels of depression according to BDI-II
scores, had lower forced expiratory volume in the 1st second (FEV1) values than those
without and greater odds for persistent, poor tolerance for physical efforts.
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Conclusions: As could be expected, an approach including both a psychiatric interview
and the use of self-administered questionnaires is likely to capture the psychiatric
outcome of patients recovered from COVID-19 better than questionnaires alone. Anxiety
and depressive symptoms at follow-up had no correlation with the severity of COVID
acute manifestations, but rather with ongoing and persistent physical symptoms. Further
studies and longer follow-up duration will allow a better understanding of the complex
relationship between residual physical symptoms, quality of life and psychological health.
Keywords: COVID-19, anxiety, depression, patients, follow-up, mid-term sequelae
INTRODUCTION
Several unpredictable and varied non-respiratory symptoms,
including neuropsychiatric ones, have been described for
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
even though the usual and primary clinical manifestation of
Coronavirus disease (COVID-19) is respiratory (1–7). Besides
strictly neurological symptoms, and persistent consequences
on cognitive function (8), psychopathological symptoms might
appear as well in patients with COVID-19 either acutely ill
or recovered. Hypotheses concerning the etiopathogenesis of
neuropsychiatric presentations in individuals with COVID-
19 include both direct (central nervous system tropism) and
indirect mechanisms (i.e., respiratory failure and related medical
procedures such as intubation, cytokine storm, host immune
response, viral infection-induced cerebrovascular accidents),
whose contribution has yet to be established and which are hard
to disentangle (9). Furthermore, adverse mental health outcomes
may be related to the overall pandemic-associated psychological
distress (fear or experience of illness, uncertainty, stigma, social
strain) (10, 11), which has been reported to be highest in
patients with COVID-19 compared to the general public and
healthcare workers, and even more likely in the vulnerable group
of psychiatric patients (12).
As shown by previous outbreaks of coronaviruses such
as those responsible of Middle East respiratory syndrome
coronavirus infection (MERS) or severe acute respiratory
syndrome (SARS) (13, 14), mental health-related symptoms
(depression, anxiety, reduced quality of life, Post Traumatic
Stress Disorder, etc.), as well as persistent impairment in
pulmonary function, muscle weakness, fatigue and pain, can
be relevant issues for patients, also in the mid-and long-term.
Therefore, it is clear that a timely assessment of psychiatric
symptoms in individuals with COVID-19 is necessary for a better
prognostic outcome (5). To achieve this objective, attention needs
to move from acute care settings to the post-acute care of patients
recovered from COVID-19. While neuro-psychiatric symptoms
acutely arising during the infection (such as delirium, transient
psychotic disorders, acute stress, sleep disorders, anxiety) have
received more attention (15, 16), the mid- and long-term
consequences in patients recovered from COVID-19 are still
unknown and poorly investigated (17).
A recent review of psychiatric symptoms or morbidities
associated with COVID-19 in infected patients and non-infected
groups (psychiatric patients, healthcare workers and non-
healthcare workers) found that only two studies, out of the
43 included, evaluated patients with confirmed COVID-19
infection. Two studies found a high level of post-traumatic stress
symptoms (PTSS) (96.2%) and significantly high prevalence of
depressive symptoms (29.2%) in newly recovered patients (18,
19). Rates of Post-Traumatic Stress Disorder (especially intrusive
images) have been found to be particularly high among patients
with more severe COVID-19 related symptoms (20). Different
studies have reported rates of sleep disturbances/disorders or
insomnia ranging from 17.7 to 35.1% (21–25). The prevalence
of depressive and anxiety symptoms among patients recovered
from COVID-19 was investigated in patients living in different
countries and rates widely varied as well, from 4.3 to 37.3% for
depression and from 6.5 to 47.8% for anxiety (21–27).
Interestingly, perceived discrimination, stigma, and social
support were suggested as predictors of mental health outcomes,
both in patients recovered and in hospital inpatients with
confirmed COVID-19 (25, 28).
From the available literature, it emerges that the
understanding of the mid- and long-term impact of COVID-
19 is far from being complete, not only in the context of a
multidisciplinary approach, but even more when focusing
on mental health/psychiatric outcomes (29). Therefore, it
is of crucial importance to deepen the neuropsychiatric
aspects of patients recovered from COVID-19, possibly
including the assessment of psychosocial impact as well as
neuroinflammation. As described above, mid-term psychiatric
outcomes of individuals recovered from COVID-19 are still
poorly investigated (21–27), although an early intervention for
the prevention of these sequelae would be recommendable,
as it is, for instance, for the psychological consequences of
the pandemic at the general population level (30). Moreover,
regarding the available literature, it should be noted that research
articles about this topic are highly heterogeneous as far as sample
size, inclusion and exclusion criteria and follow-up duration
(only a few studies followed-up patients for more than 2 months)
are concerned; patients’ assessment is based mainly on different
kind of assessment tools and self-administered questionnaires
which do not equate a clinical diagnosis (22, 23, 26, 27). The
importance of the topic is further underscored by the fact
that recent literature introduced the term “Long COVID” in
order to describe people recovered from COVID-19, but still
having lasting symptoms, such as fatigue, muscle weakness, sleep
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difficulties, anxiety or depression (21, 31). It has been suggested
that scientific studies must better identify the heterogeneity of
Long COVID, considering that it might represent another public
health crisis (32).
In the context of a multi-disciplinary follow-up project (33),
our aim was to investigate the mid-term psychiatric outcomes
(anxiety, depressive symptoms, post-traumatic stress symptoms,
resilience) of patients recovered from COVID-19, followed-up
3 to 4 months after discharge from hospital. For this purpose,
our assessment included both a thorough clinical interview
performed by an experienced psychiatrist and the use of self-
administered, validated questionnaires. Previously published
data from this project have already highlighted that 17% of
patients undergoing the multi-disciplinary assessment showed
post-traumatic stress symptoms (moderate-severe scores at the
Impact of Event Scale); in the current paper, we will focus on
anxiety and depressive symptoms.
Considering the currently available research about this
topic, we were particularly interested in assessing the possible
differences between anxiety and depressive symptoms as
identified by the clinical interview performed by an experienced
psychiatrist and as assessed with self-administered screening
questionnaires. Furthermore, we investigated the possible
association of the mid-term mental health consequences of
the COVID-19 infection with patients’ clinical current status,
persistent physical impairment and severity of acute phase of the
disease.We postulated that the persistence of physical symptoms,
especially respiratory ones, could be the main driver in the
maintenance of the mid-term mental health consequences of the
COVID-19 infection, rather than the severity of the acute disease.
METHODS
A prospective study was performed; more details about the
methodology of the study and recruitment procedures can be
found elsewhere (33). We contacted by phone, around 4 months
after discharge [median time after discharge 131 (119–145)
days], 767 consecutive patients, older than 18 years of age,
admitted for COVID-19 and then discharged from the University
Hospital “AOU Maggiore della Carità” in Novara (Northern
Italy) between 1st March 2020 and 29th June 2020. Out of these
767 patients, 35 (4.6%) had died since hospital discharge and
494 (64.4%) declined participation. We eventually enrolled 238
(31.0%) subjects who gave their informed consent to participate.
No exclusion criterion was applied, except for unwillingness to
provide consent (further details about enrollment have been
described elsewhere) (33). An electronic case report form was
generated using the Research Electronic Data Capture software
(REDCap, Vanderbilt University) for clinical data collection, and
a unique pseudonymized code was attributed to each patient
included into the study. The study protocol was approved by the
local ethical committee (Comitato Etico Interaziendale Novara;
IRB code CE 117/20) and research was conducted according to
the principles of the Declaration of Helsinki.
Information was gathered about: socio-demographic features,
symptoms during the acute COVID-19 phase, comorbidities,
home medications and complications during the hospital stay.
The multi-disciplinary team involved in this clinical and research
project performed a thorough assessment of patients who, a
few days after the phone contact, were invited to attend an
outpatient visit at the hospital, including the following: internal
medicine visit to ascertain patients’ symptoms at follow-up and
new diagnoses received after hospital discharge; pneumology visit
including spirometry; physiatric visit with physical performance
tests; psychiatric assessment, including a thorough psychiatric
interview and self-administered questionnaires which were
filled in during the hospital stay for the outpatient visit, as
detailed below.
In this paper, we specifically focused on the following
socio-demographic and clinical variables: age, gender, smoking
attitude, history of chronic obstructive pulmonary disease
(COPD), hypertension, diabetes, ischemic cardiac disease,
obesity, type of oxygen support during hospitalization, Intensive
Care Unit (ICU) admission. At follow-up we recorded: the forced
expiratory volume in the 1st second (FEV1), the forced vital
capacity (FVC), the diffusing capacity of the lung for carbon
monoxide (DLCO), the complaint of dyspnea and the perceived
tolerance to physical efforts.
Regarding psychiatric assessment at follow-up, patients were
interviewed face-to-face by an experienced psychiatrist, trained
in the use of the Mini-International Neuropsychiatric Interview
(MINI) (34), with structured and unstructured questions about
current mental health status; previous psychiatric history (being
already treated by psychiatric services; a history of anxiety and/or
depression); depressive and anxiety symptoms, changes in sleep
and eating patterns since discharge from hospital. Interviewers
rated the questions concerning depressive and anxiety symptoms,
and changes in sleep and eating patterns as follows: a “yes”
answer was attributed in those cases where a clinically relevant
symptom emerged, a “no” answer in all other cases. Information
was recorded about the outcome of the psychiatric consultation
(no further indication; referral to further psychiatric care for
support or medication). Furthermore, patients were asked to fill
in the following self-administered measures during their hospital
stay for the outpatient, multidisciplinary follow-up visit: Beck
Anxiety Inventory (BAI), Beck Depression Inventory (BDI-II),
Resilience Scale for Adults (RSA) and the Impact of Event Scale




The MINI (34) is a brief structured interview developed on the
basis of DSM-IV and ICD-10 in order to identify psychiatric
diagnosis. The administration time is approximately 15min and
it was designed with the aim to be a short, simple, but highly
sensitive tool. For our study, we adopted the A, E, O modules
to screen for major depressive disorder, panic disorder, and
generalized anxiety disorder.
Beck Anxiety Inventory (BAI)
It is a self-report 21-item questionnaire measuring the emotional,
physiological and cognitive symptoms of anxiety as well as its
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severity (35). Each item is rated on a 4-points scale (from 0 to
3). The following levels of anxiety are identified according to
the total score: minimum (0–21); moderate (22–35); high (>36).
For the subsequent analyses, we grouped together participants
with a total score higher that 21; in other words, we categorized
participants in those with minimum BAI scores and those
with higher scores (moderate-severe). BAI’s internal consistency
measured by Cronbach Alpha is 0.94 (36).
Beck Depression Inventory (BDI-II-II)
It is one of the most used measures for depression (37). It is
a self-report questionnaire with 21-item rated on a 4-points
scale (from 0 to 3), asking about symptoms in the last 2 weeks.
Total scores suggest different levels of depression: minimum (0–
13); mild (14–19); moderate (20–28); severe (29–63). Internal
consistency measured by Cronbach Alpha is 0.86 for the mental
component, 0.65 for the somatic component (38). For the
subsequent analyses, we grouped together participants with a
total score higher than 13; in other words, we categorized
participants in those withminimumBDI-II scores and those with
higher scores (mild-moderate-severe).
Resilience Scale for Adults (RSA)
It is a self-administered scale consisting of 33 items that examine
intra- and inter-personal protective factors deemed capable of
facilitating adaptation in the face of psychosocial adversity (39).
The factor analysis identified six factors: positive perception
of self, positive perception of the future, social competence,
structured style, family cohesion and social resources. There are
no cut-offs for this scale; the higher the total score, the greater is
the person’s overall resilience. Internal consistency evaluated by
Cronbach alpha is 0.86 (40).
Impact of Event Scale (IES)
It is a 15-item self-rated 4-point scale based on how often an
event has occurred in the past 7 days (0 indicates not at all; 1,
rarely; 3, sometimes; 5, often), in order to assess the presence of
post-traumatic stress (PTS) symptoms (41). Besides the IES total
subjective stress score, 2 subscales are identified. One subscale
(7 items) measures intrusive symptoms (intrusive thoughts,
nightmares, intrusive feelings and imagery), with scores ranging
from 0 to 35; the other subscale (8 items) measures avoidance
symptoms (numbing of responsiveness and avoidance of feelings,
situations, or ideas), with scores ranging from 0 to 40. Internal
consistency coefficients for intrusion is 0.84, for avoidance is
0.71 (42).
Statistical Analysis
Enrolled patients were 238, but full data for the psychometric
questionnaires were available for 237 of them (1 patients did not
fill all of them and hence was excluded from the current analyses).
Data were analyzed using the statistical software MedCalc
v19.2.6 (43). Normality was assessed by Shapiro-Wilk test. The
measures of centrality and dispersion chosen for continuous
variables were medians and [25th-75th percentile].
We firstly established the prevalence of anxiety and depressive
symptoms according to the clinical interview and we assessed
the level of anxiety and depression as measured by the BAI
and BDI-II. We then evaluated the possible associations between
persistence of anxiety and depressive symptoms (both as assessed
at the clinical interview and according to BAI and BDI-II) and the
following continuous or categorical variables, related to: patients’
demographic features (age and gender), length of hospital in-stay,
patients’ comorbidities such as COPD, hypertension, diabetes,
ischemic cardiac disease, obesity, previous history of anxiety
and/or depression, smoking attitude, being already treated
by psychiatric services, questionnaire scores (IES and RSA);
severity of acute phase (ICU admission and modality of oxygen
delivery during hospitalization); persistent physical sequelae
(DLCO, FEV1, FVC, presence of dyspnea, poor tolerance to
physical efforts, changes in appetite and sleep patterns); being
recommended further psychiatric consultation. For this purpose,
we run a univariate analysis, first: comparisons between groups
were performed by the Mann-Whitney test for continuous
variables (age, DLCO, FEV1, FVC, RSA total score). Categorical
variables were reported as frequencies and percentages and
analyzed through the Pearson’s chi-square or Fisher’s exact test,
as appropriate. All the associations with a p value < 0.20 were
then included in logistic regression models.
RESULTS
General Features and Outcome of the
Psychiatric Interview
Patients’ general features have already been described elsewhere
(33). According to the information gathered in the context of
the psychiatric interview, 32 participants (13.5%) were already
treated by psychiatric services; 11 (4.6%) had a previous history
of anxiety and/or depression.
Changes in appetite and sleep patterns emerged at the clinical
interview for 37 (15.6%) and 74 (31.2%) of patients, respectively.
Data about anxiety and depressive symptoms at the
psychiatric interview are described in the sections below.
According to BAI and BDI-II scores, patients were categorized in
two groups, as described in the methods; 17 (7.1%) participants
had moderate-severe anxiety levels according to the BAI,
while the BDI-II found mild to severe depression scores in 25
(10.5%) patients.
After the psychiatric interview and assessment, 26 (11%)
participants were referred to further psychiatric consultation.
Anxiety at the Psychiatric Interview
Anxiety symptoms were found in 78 patients (32.9%) at the
clinical interview. When comparing patients with and without
anxiety symptoms at the psychiatric interview, no difference
was found in BAI categorization (p = 0.522). On the other
hand, differences were found in depressive symptoms, sleep and
appetite patterns as assessed at the psychiatric interview, being
already treated by psychiatric services, being recommended
further psychiatric consultation (Table 1). Moreover, the
univariate analysis found that participants with persistent
anxiety symptoms at the psychiatric interview were significantly
younger than those without (median age of those with anxiety
vs. those without, 56 vs. 62, p = 0.02) (Table 2); nonetheless,
this result was not supported by the logistic regression analysis
(Table 3).
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TABLE 1 | Anxiety as assessed at the psychiatric interview and with the BAI: chi squared test.
Anxiety at the clinical interview p BAI total score p
Yes No Minimum (<22) Moderate-high (≥22)
N (%) N (%) N (%) N (%)
IES total score Minimal (0–8) 45 (57.70) 90 (56.60) 0.641 133 (60.45) 2 (11.76) <0.001
Low (9–25) 19 (24.36) 42 (26.41) 56 (25.45) 5 (29.41)
Moderate (26–43) 11 (14.10) 16 (10.07) 23 (10.45) 4 (23.53)
High (>44) 3 (3.84) 11 (6.92) 8 (3.64) 6 (35.29)
Depression at the clinical
interview
Yes 46 (58.97) 24 (15.09) <0.001 65 (29.55) 5 (29.41) 1.000
No 32 (41.03) 135 (84.49) 155 (70.45) 12 (70.59)
Sent for further psychiatric
referral/consultation
Yes 24 (30.77) 2 (1.28) <0.001 24 (10.90) 2 (11.76) 1.000
No 54 (69.23) 157 (98.74) 196 (89.10) 15 (88.24)
History of anxiety and/or
depression
Yes 6 (7.70) 5 (3.14) 0.185 10 (4.55) 16 (94.11) 0.801
No 72 (92.30) 154 (96.86) 210 (94.45) 1 (5.88)
Already treated by
psychiatric services
Yes 27 (34.61) 5 (3.14) <0.001 30 (13.63) 2 (11.76) 1.000
No 51 (65.38) 154 (96.85) 190 (86.64) 15 (88.24)
Exercise intolerance/poor
tolerance to physical efforts
Yes 57 (73.07) 130 (81.76) 0.131 44 (0.20) 6 (35.40) 0.212
No 21 (26.93) 29 (18.24) 176 (0.80) 11 (64.70)
Gender Male 40 (51.28) 101 (63.52) 0.091 131 (59.55) 10 (58.82) 1.000
Female 38 (48.72) 58 (36.48) 89 (40.45) 7 (41.18)
Sleep problems at the
clinical interview
Yes 46 (58.97) 28 (17.61) <0.001 68 (30.90) 6 (35.40) 0.787
No 32 (41.03) 131(82.39) 152 (69.10) 11 (64.70)
Appetite problems at the
clinical interview
Yes 24 (30.77) 13 (8.18) <0.001 34 (15.5) 3 (17.6) 0.734
No 54 (69.23) 146 (91.82) 186 (84.5) 14 (82.4)
COPD Yes 6 (7.70) 8 (5.03) 0.40 14 (6.36) 0 (0.00) 0.61
No 72 (92.30) 151 (94.97) 206 (93.64) 17 (100)
Ischemic heart disease Yes 3 (3.85) 18 (11.32) 0.09 21 (9.54) 0 (0.00) 0.37
No 75 (96.15) 141 (88.68) 199 (90.46) 17 (100.00)
Dyspnea Yes 5 (6.41) 8 (5.03) 0.76 12 (5.45) 1 (5.88) 1.00
No 73 (93.59) 151 (94.97) 208 (94.55) 16 (94.12)
Diabetes Yes 10 (12.82) 26 (16.35) 0.57 34 (15.45) 2 (11.76) 1.00
No 68 (87.18) 133 (83.65) 186 (84.55) 15 (88.24)
Hypertension Yes 30 (38.46) 67 (42.14) 0.67 93 (42.27) 4 (23.53) 0.20
No 48 (61.54) 92 (57.86) 127 (57.73) 13 (76.47)
Obesity Yes 11 (14.10) 14 (8.80) 0.26 23 (10.45) 2 (11.76) 0.70
No 67 (85.90) 145 (91.20) 197 (89.55) 15 (88.24)
Type of oxygen support NC 29 (37.18) 37 (23.27) 0.15 61 (27.73) 5 (29.41) 0.68
VM 28 (35.90) 72 (45.28) 95 (43.18) 5 (29.41)
CPAP/NIV 14 (17.95) 36 (22.64) 45 (20.45) 5 (29.41)
EI 7 (8.97) 14 (8.81) 19 (8.64) 2 (11.76)
ICU admission Yes 9 (11.54) 19 (11.95) 1.00 24 (10.91) 4 (23.53) 0.12
No 69 (88.46) 140 (88.05) 196 (89.09) 13 (76.47)
Smoking Never 46 (58.97) 92 (57.86) 0.99 129 (58.64) 9 (52.94) 0.61
Current 8 (10.26) 17 (10.69) 22 (10.00) 3 (17.65)
Former 24 (30.77) 50 (31.45) 69 (31.36) 5 (29.41)
BAI, Beck Anxiety Inventory; COPD, Chronic Obstructive Pulmonary Disease; CPAP/NIV, Continuous Positive Airway Pressure/Non-Invasive Ventilation; EI, endo-tracheal intubation;
IES, Impact of Event Scale; NC, nasal cannulae; VM, Venturi Mask.
The P-values of significant findings are written in bold.
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Anxiety According to BAI Score
As described in the methods, patients were categorized in two
groups according to BAI scores (minimal vs. higher scores).
The two groups showed no statistically significant difference in
changes in sleep and appetite patterns, being already treated
by psychiatric services, being sent for further psychiatric
consultation (Table 1). The two groups differed in post-traumatic
stress symptoms, as patients in the moderate-severe anxiety
BAI category were more likely to fall in the moderate-high IES
score category (Table 1). Furthermore, no statistically significant
differences were found between the two groups regarding any
of the socio-demographic and clinical continuous variables we
gathered (age, DLCO, FEV1, FVC, IES score, RSA Total score,
see Table 2).
The logistic regression yielded no statistically significant result
except for the IES score (P = 0.0001; OR 3.14, 95% CI 1.88–5.25)
(Table 3).
Depressive Symptoms at the Psychiatric
Interview
Depressive symptoms at the clinical interview were found in 70
patients (29.5%). Patients with depressive symptoms according
to the psychiatric interview, compared to those without,
more frequently had mild to severe BDI-II scores. Statistically
significant differences between the two groups included anxiety
and changes in sleep and appetite patterns as assessed at
the psychiatric interview; being suggested further psychiatric
consultation. Further associations emerged with female gender
(p= 0.0001) and COPD (p= 0.03) (Table 4).
Participants with depressive symptoms, as identified by the
clinical interview, had lower FEV1 values than those who did
not (p = 0.0231; median 97 [90.0–104.7] vs. 102 [93.5–113.5])
(Table 5), but showed no difference in the other continuous
variables assessed (age, DLCO, FVC, RSA total score).
When run for depressive symptoms at the psychiatric
interview, the logistic regression highlighted statistically
significant results, showing higher odds in females (OR 0.34;
95% CI 0.18–0.64; p = 0.0009), patients with COPD (OR 3.39;
95% CI 1.02–11.29; p= 0.04) and with persistent, poor tolerance
to physical efforts at follow-up (OR 2.24; 95% CI 1.08–4.67;
p= 0.03) (Table 6).
Depression According to BDI-II Scores
According to the BDI-II categorization described in the methods,
compared to those with minimal depression according to the
BDI-II score, a higher rate of patients in the mild to severe
depression group was already treated by psychiatric services, had
a previous history of anxiety/depression, and was sent for further
TABLE 2 | Anxiety as assessed at the psychiatric interview and with the BAI: Mann-Whitney test results.
Anxiety at the clinical interview p BAI total score p









Age (years) 56.00 [47.00–68.00] 62.00 [52.00–71.00] 0.02 61.00 [51.00–71.00] 53.00 [43.25–67.50] 0.18
DLCO (% predicted value) 80.50 [67.00–90.00] 78.00 [69.00–87.00] 0.34 79.00 [69.00–89.00] 74.50 [60.50–87.50] 0.38
FEV1 (% predicted value) 100.00 [89.25–113.75] 101.00 [92.50–111.00] 0.84 101.00 [92.00–112.00] 99.00 [85.50–113.50] 0.70
FVC (% predicted value) 100.00 [90.00–111.00] 97.00 [90.00–108.00] 0.41 98.00 [90.00–109.00] 98.50 [87.00–110.00] 0.97
RSA total score 134.00 [119.25–147.00] 137.00 [118.00–146.00] 0.95 135.00 [120.00–147.50] 134.00 [111.25–143.75] 0.29
Length of hospital in-stay (days) 8 [4–16] 9 [8–11] 0.33 9 [5–16] 7 [4–14] 0.49
BAI, Beck Anxiety Inventory; DLCO, diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in the 1st second; FVC, forced vital capacity; RSA, Resilience
Scale for Adults.
The P-values of significant findings are written in bold.
TABLE 3 | Logistic regression model for anxiety as assessed at the psychiatric interview and with the BAI.
Anxiety at the clinical interview BAI Total score (≥22)
OR (95% CI) p-value OR (95% CI) p-value
Age 0.98 (0.96–1.01) 0.15 Age 0.98 (0.95–1.03) 0.53
Exercise intolerance/Poor
tolerance to physical efforts
1.66 (0.85–3.24) 0.14 Exercise intolerance/Poor
tolerance to physical efforts
1.25 (0.36–4.37) 0.72
Gender 0.68 (0.38–1.22) 0.19 ICU admission 1.45 (0.34–6.02) 0.61
History of anxiety and depression 2.57 (0.71–9.29) 0.15 IES Total score category 3.14 (1.88–5.25) <0.001
Oxygen support 0.85 (0.62–1.66) 0.31 Hypertension 0.52 (0.15–1.83) 0.31
Ischemic heart disease 0.43 (0.12–1.58) 0.20
BAI, Beck Anxiety Inventory; ICU, Intensive Care Unit; IES, Impact of Event Scale.
The P-values of significant findings are written in bold.
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TABLE 4 | Depressive symptoms as assessed at the psychiatric interview and with the BDI-II: chi squared test.
Depressive symptoms at the clinical interview p BDI-II total score p
Yes No Minimum ≤13 Mild to severe >13
N (%) N (%) N (%) N (%)
IES total score Minimal (0–8) 39 (55.72) 96 (57.48) 0.97 121 (57.07) 14 (56) 0.53
Low (9–25) 18 (25.72) 43 (25.75) 54 (25.47) 7 (28)
Moderate (26–43) 9 (12.85) 18 (10.78) 23 (10.85) 4 (16)
High (>44) 4 (5.71) 10 (5.99) 14 (6.61) 0 (0)
Sent for further psychiatric
referral/consultation
Yes 21 (30.) 5 (2.99) <0.001 17 (8.02) 9 (36) <0.001
No 49 (70) 162 (97.01) 195 (91.98) 16 (64)
History of anxiety and/or
depression
Yes 64 (91.42) 162 (9.7) 0.0876 6 (2.83) 5 (20) 0.001
No 6 (8.58) 5 (90.3) 206 (97.17) 20 (80)
Already treated by
psychiatric services
Yes 22 (31.42) 10 (5.99) <0.001 24 (11.32) 8 (32) 0.009
No 48 (68.58) 157 (94.01) 188 (88.68) 17 (68)
Exercise intolerance/poor
tolerance to physical efforts
Yes 19 (27.14) 31 (18.56.) 0.16 40 (18.87) 10 (40) 0.02
No 51 (72.86) 136 (81.44) 172 (81.13) 15 (60)
Gender Male 28 (40) 113 (67.66) <0.001 132 (62.26) 9 (36) 0.017
Female 42 (60) 54 (32.34) 80 (37.74) 16 (64)
Sleep problems at the
clinical interview
Yes 39 (55.71) 35 (20.96) <0.001 59 (27.83) 15 (60) 0.002
No 31 (44.29) 132 (79.04) 153 (72.17) 10 (40)
Appetite problems at the
clinical interview
Yes 23 (32.86) 14 (8.38) <0.001 29 (13.68) 8 (32) 0.035
No 47 (67.14) 153 (91.62) 183 (86.32) 17 (68)
Anxiety at the clinical
interview
Yes 46 (65.71) 32 (19.16) <0.001 62 (29.24) 16 (64) 0.0049
No 24 (34.29) 135 (80.84) 150 (70.76) 9 (36)
COPD Yes 8 (11.43) 6 (3.59) 0.03 12 (5.66) 2 (8.00) 0.65
No 62 (88.57) 161 (96.41) 200 (94.34) 23 (92.00)
Ischemic heart disease Yes 4 (5.71) 17 (10.18) 0.32 20 (9.43) 1 (4.00) 0.71
No 66 (94.29) 150 (89.82) 192 (90.57) 24 (96.00)
Dyspnea Yes 6 (8.57) 7 (4.19) 0.21 12 (5.66) 1 (4.00) 1.00
No 64 (91.43) 160 (95.81) 200 (94.34) 24 (96.00)
Diabetes Yes 8 (11.43) 28 (16.77) 0.33 35 (16.51) 1 (4.00) 0.14
No 62 (88.57) 139 (83.23) 177 (83.49) 24 (96.00)
Hypertension Yes 23 (32.86) 74 (44.31) 0.11 84 (39.62) 13 (52.00) 0.28
No 47 (67.14) 93 (55.69) 128 (60.38) 12 (48.00)
Obesity Yes 7 (10.00) 18 (10.78) 1.00 20 (9.43) 5 (20.00) 0.16
No 63 (90.00) 149 (89.22) 192 (90.57) 20 (80.00)
Type of oxygen support NC 27 (38.57) 39 (23.35) 0.10 57 (26.89) 9 (36.00) 0.61
VM 27 (38.57) 73 (43.72) 89 (41.98) 11 (44.00)
CPAP/NIV 12 (17.15) 38 (22.75) 47 (22.17) 3 (12.00)
EI 4 (5.71) 17 (10.18) 19 (8.96) 2 (8.00)
ICU admission Yes 7 (10.00) 21 (12.57) 0.66 24 (11.32) 4 (16.00) 0.51
No 63 (90.00) 146 (87.43) 188 (88.68) 21 (84.00)
Smoking Never 43 (61.43) 95 (56.89) 0.53 122 (57.55) 16 (64.00) 0.52
Current 5 (7.14) 20 (11.98) 24 (11.32) 1 (4.00)
Former 22 (31.43) 52 (31.13) 66 (31.13) 8 (32.00)
BDI-II, Beck Depression Anxiety Inventory-II; COPD, Chronic Obstructive Pulmonary Disease; CPAP/NIV, Continuous Positive Airway Pressure/Non-Invasive Ventilation; EI, endo-tracheal
intubation; IES, Impact of Event Scale; NC, nasal cannulae; VM, Venturi Mask.
The P-values of significant findings are written in bold.
psychiatric consultation. Furthermore, patients in the mild to
severe group according to the BDI-II scores categorization more
frequently showed anxiety at the clinical interview, as well as
changes in sleep and appetite patterns since discharge from
hospital (Table 4).
When dividing participants according to BDI-II scores
(minimal vs. mild to severe depression) no difference was
found in the socio-demographic and clinical continuous variables
investigated (age, DLCO, FVC, IES score, RSA Total score),
except for FEV1. Participants with mild to severe levels of
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TABLE 5 | Depressive symptoms as assessed at the psychiatric interview and with the BDI-II: Mann-Whitney test results.
Depressive symptoms at the clinical interview p BDI-II total score p









Age (years) 60.50 [49.00–72.00] 61.00 [50.25–69.00] 0.67 61.00 [50.00–71.00] 59 [48.88–65.50] 0.57
DLCO (% predicted value) 75.00 [67.50–87.50] 80.00 [70.00–89.00] 0.39 79.00 [70.00–88.00] 72.00 [59.50–93.00] 0.42
FEV1 (% predicted value) 97.00 [90.00–104.50] 102.50 [93.50–1113.50] 0.02 102.00 [92.00–113.00] 95.00 [88.00–103.00] 0.04
FVC (% predicted value) 99.00 [89.25–106.75] 98.00 [90.00–111.00] 0.48 99.00 [90.00–109.00] 95.50 [90.50–101.00] 0.31
RSA total score 133.55 [113.00–145.00] 137.00 [120.00–148.75] 0.19 134.50 [120.00–147.00] 137.00 [102.75–149.25] 0.41
Length of hospital in-stay (days) 10 [5–18] 9 [5–16] 0.84 9 [5–16] 9 [4–16] 0.66
BDI-II, Beck Depression Inventory-II; DLCO, diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in the 1st second; FVC, forced vital capacity; RSA,
Resilience Scale for Adults.
The P-values of significant findings are written in bold.
TABLE 6 | Logistic regression model for depressive symptoms as assessed at the psychiatric interview and with the BDI-II.
Depressive symptoms at the clinical interview BDI-II Total score (>13)
OR (95% CI) p-value OR (95% CI) p-value
Exercise intolerance/Poor
tolerance to physical efforts
2.24 (1.08–4.67) 0.03 Exercise intolerance/Poor
tolerance to physical efforts
3.39 (1.25–9.21) 0.02
History of anxiety and depression 2.66 (0.68–10.41) 0.16 History of anxiety and depression 11.10 (2.64–46.62) 0.001
Gender 0.34 (0.18–0.64) <0.001 Gender 0.39 (0.15–1.03) 0.06
RSA Total Score 0.99 (0.98–1.01) 0.79 Obesity 4.03 (1.02–15.89) 0.04
Fev1 0.98 (0.97–1.01) 0.29 Fev1 0.97 (0.95–1.00) 0.09
Oxygen support 0.72 (0.49–1.08) 0.07 Diabetes 0.10 (0.01–1.04) 0.05
COPD 3.39 (1.02–11.29) 0.046
Hypertension 0.65 (0.33–1.29) 0.22
BDI-II, Beck Depression Inventory; COPD, Chronic Obstructive Pulmonary Disease; FEV1, forced expiratory volume in the 1st second; RSA, Resilience Scale for Adults.
The P-values of significant findings are written in bold.
depression according to the BDI-II had lower FEV1 values than
those with minimal depression (p = 0.044, median 95 [88–103]
vs. 102 [92–113]) (Table 5).
The logistic regression found associations between mild to
severe BDI-II score, obesity (OR 4.03; 95% CI 1.02–15.89; p =
0.04), poor tolerance to physical efforts (OR 3.39; 95% CI 1.25–
9.21; p= 0.02) and previous history of anxiety and/or depression
(OR 11.10; 95% CI 2.6–46.62; p= 0.001) (Table 6).
DISCUSSION
In our sample, at the psychiatric assessment 32.9 and 29.5%
of participants showed anxiety and depressive symptoms since
hospital discharge, respectively. Changes in appetite and sleep
patterns emerged for 15.6 and 31.2% of patients at follow-
up. According to the self-administered questionnaires, 7.1% of
participants had moderate-severe anxiety levels (BAI), while
10.5% had mild to severe depression (BDI-II). Thirty-two
participants (13.5%) were already treated by psychiatric services
and after the psychiatric interview and assessment, 26 (11%)
participants were referred to further psychiatric consultation.
The prevalence rates we found were lower than those
described by a recent systematic review and random-effects
meta-analysis which reported the following pooled prevalence
values: 45% for depression (95% CI: 37–54%, I2 = 96%), 47%
for anxiety (95% CI: 37–57%, I2 = 97%), and 34% for sleeping
disturbances (95% CI: 19–50%, I2= 98%) (16). Nonetheless, this
systematic review did not specify about follow-up timing, and
the Authors underscored that according to the screening tools
used, depression and anxiety prevalence estimates highly varied.
Some recent reports about the mid-term psychiatric outcomes
in COVID-19 patients described indeed a wide range of rates of
depressive symptoms, from 4.3 to 37.3% (22, 23, 26, 27, 44, 45), as
well as for anxiety ones, from 6.5 to 47.8% (22, 23, 26, 27, 44, 45).
Nonetheless, the possibility to compare results from different
studies may be hard: there are many inconsistencies concerning
sample selection and follow-up approach; most of the available
studies lack exhaustive information, also as far as psychiatric
history and medications are concerned. Furthermore, in most
studies they were just used self-administered questionnaires,
while in others, as the one by Sykes, specific symptoms were
assessed directly asking patients whether or not they were
currently experiencing them (23). In our study, according to the
psychiatrists’ clinical assessment, 32.9% of the sample had anxiety
symptoms while anxiety as measured by the BAI was moderate
to severe in 7.1% of participants. Some considerations can be
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made about this finding: first, the BAI is not a diagnostic tool
and certainly a self-administered questionnaire cannot equate
a clinical diagnosis; second, questions in the BAI specifically
refer to the previous 1 week, while in the context of the
clinical interview a longer period of time was assessed to
establish whether anxiety symptoms were indeed present or not;
furthermore, it is possible that the factors influencing anxiety
during clinical interview and anxiety as measured with the BAI
might differ. For instance, as post-traumatic stress symptoms
were higher in patients with moderate-severe BAI score, but not
in those with anxiety at the clinical interview, we cannot exclude
that they played a role. It has been suggested that post-traumatic
stress might be better captured by new tools, developed ad hoc for
the current pandemic, rather than by already existing ones (46),
while similar considerations have not yet been raised for other
psychological dimensions, symptoms or constructs.
As far as depression is concerned, the clinical interview
highlighted depression in 29.5% of the sample, while 10.5% of
participants showed mild to severe levels of depression according
to the BDI-II. Findings emerging from the self-administered
questionnaire (BDI-II) and the assessment of depressive
symptoms at the clinical interview seemed more consistent than
those regarding anxiety and were not correlated with post-
traumatic symptoms (no correlation with the IES scale). In
patients with clinically assessed depressive symptoms it was also
more frequent a previous history of anxiety and/or depression
and having already been treated by psychiatric services.
In any case, as could be expected, the outcome of the clinical
interview was consistent with the choice to suggest patients
further psychiatric consultations. Interestingly, the severity
of acute COVID manifestations during previous inpatient
treatment (e.g., ICU admission, type of oxygen support needed)
showed no correlation with anxiety nor with depression,
either clinically assessed or self-reported. Currently available
studies about the mid-term psychiatric outcomes in COVID-
19 patients have yielded mixed results concerning this issue.
Huang found more problems in terms of anxiety and depression,
in participants with greatest disease severity during hospital
stay, compared to those who needed hospital admission but
no oxygen supplementation (21). On the other hand, our
results are consistent with other previous reports, which
found no correlation between pneumonia severity, fatigue and
psychological morbidities in COVID-19 patients (23, 27, 28, 44).
Interestingly, associations have been suggested between
depression or anxiety and persistent breathlessness (27) or
physical symptoms at follow-up (44). The existing literature thus
seems to suggest that it might be the persistence of physical
symptoms, especially respiratory ones, to play a stronger role in
the maintenance of the mid-term mental health consequences of
the COVID-19 infection, rather than the severity of the acute
disease. Our findings concerning depression seem to support
this hypothesis. Actually, in our sample patients with depressive
symptoms at the clinical interview, as well as those with mild
to severe levels of depression according to BDI-II scores, had
lower FEV1 values than those without. Furthermore, we found
that patients with depressive symptoms as assessed at the clinical
interview, as well as those scoring higher on the BDI-II, had
greater odds for persistent, poor tolerance for physical efforts.
Despite we failed to find any statistically significant results
concerning resilience, it cannot be excluded that potentially
protective factors, such as resilience, coping skills, post-traumatic
growth, faith, and support from family and friends might play a
role on the psychiatric outcome of the COVID-19 infection (28).
To our knowledge only the study by Venturelli et al. (26) assessed
resilience, and as in our sample, the great majority of respondents
seemed to have enough resources to react. Nonetheless, the
lack of baseline data and of other comparable studies does
not currently allow the understanding of the possible role of a
construct like the one of resilience inmediating persistent anxiety
or depression symptoms and post-traumatic stress ones.
Limitations
As already pointed out, a key limitation of our research
was patients’ recruitment and selection, with a large number
of patients who denied participation after being contacted
by phone; this might have generated a selection bias, and
the actual proportion of subjects with functional impairment
and/or psychological sequelae might have been lower if all
had participated. Unfortunately, as for similar studies, no
pre-COVID 19 baseline data were available. Nonetheless,
differently by most of the available studies about the topic, we
asked participants information about their previous psychiatric
history and contact with mental health services, even though
information about medication treatment (e.g., antidepressants)
was not systematically gathered and hence was not available for
the analysis. Furthermore, we did not limit our assessment to
subjective, self-administered questionnaires, whose pathological
scores cannot be equated to a clinical diagnosis, but we performed
a face-to-face psychiatric interview. As far as the MINI interview
is concerned, it should be underscored that some researchers have
suggested that, compared to the SCID, the MINI interview could
classify major depression more often (47).
We believe that our multi-disciplinary assessment and the
specific, multi-faceted approach we adopted for the psychiatric
follow-up of COVID patients, represent relevant strengths of our
research project.
CONCLUSION
Follow-up studies should aim to identify those patients who
might benefit more from further referral and care. Briefly,
according to our findings, the self-administered measure we
used for anxiety assessment (BAI) did not seem to differentiate
well those who were referred for further consultation and
those who were not, while the one we adopted for depression
assessment (BDI-II) performed better. As could be expected
according to clinical experience, the psychiatric interview
effectively differentiated further referrals. It is important an
approach including both a clinical interview conducted by
an experienced psychiatrist and the use of self-administered
questionnaires. This double approach is more likely to capture
the psychiatric symptoms of patients recovered from COVID-
19, and eventually identify patients who might benefit for
further referral. Nonetheless, the availability of resources
should be considered, also in the context of the continuing
COVID-19 related emergency. Interestingly, the severity of
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COVID acute manifestations showed no correlation with anxiety
nor with depression, but the persistence of respiratory and
physical symptoms, even after the acute phase, correlated with
psychological and psychopathological symptoms. Further studies
and longer follow-up duration will allow a better understanding
of the complex relationship between residual physical symptoms,
quality of life and psychological health. For this purpose, our
research group is planning the 1-year follow-up involving the
participants to the current study.
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